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Oral controlled-release formulations are playing an ever-increasing role in opioid therapy; 
however, little is known about their influence on the relationship between pharmacokinetics and 
pharmacodynamics. 
The study aim was to characterise the pharmacokinetic-pharmacodynamics of two controlled-
release tablet formulations and a liquid formulation of oxycodone in healthy, opioid-naïve 
subjects, which can serve as a reference for future patient studies. 
A semi-double-blinded, three-way cross-over study was conducted, with fifteen healthy subjects 
receiving two differently designed 20 mg monophasic controlled-release oxycodone tablets and 10 
mg oral solution oxycodone in a randomised order. Venous plasma concentrations and pupil 
diameter were determined pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.33, 2.66, 3, 3.33, 3.66, 4, 5, 6, 
8, 12 and 24 h post-dose. 
Oxycodone pharmacokinetics were best described by a two-compartment model with first order 
absorption. The controlled-release formulations had an absorption lag of 0.23 h and a slower 
absorption rate constant (kaCR = 0.19 h-1) compared to the oral solution (kaSOL = 0.94 h-1).  Effects 
on pupil diameter were delayed relative to plasma (14 min half-life) for all formulations and were 
best described by a proportional Emax model. The plasma concentration of oxycodone at half-
maximum effect was lower in males (31.1 g/L) compared to females (52.8 g/L; P <0.001). 
The absorption profile of controlled-release oxycodone formulations provided a prolonged onset 
and offset of action compared to oral solution oxycodone. The controlled-release formulations 
showed no differences in pharmacokinetic and pharmacodynamic parameters suggesting that both 
may be used interchangeably in humans with normal gastrointestinal function.
Introduction 
Pain is a complex pathology causing aggravation, depression, labour incapability and a deprived 
quality of life for many patients. Consequently, it can be a huge financial burden for societies 
worldwide [1]. Pain management is complex and opioids are often used in the treatment of chronic 
moderate to severe pain [2]. Oral controlled-release formulations are playing an ever-increasing 
role in drug therapy mainly due to their advantages of increasing dosing intervals and decreasing 
fluctuations in plasma concentrations, which improves patient compliance, efficacy and reduces 
occurrence of side-effects such as sedation [3–5]. However, drug release, and hence absorption, A
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from controlled-release formulations is highly dependent on formulation design, physiochemical 
drug properties and gastrointestinal physiology, where factors such as gastrointestinal fluid 
composition, motility, pH, transit time, surface area and/or distribution of metabolising enzymes 
and transporters play a crucial role [6]. Several controlled-release delivery systems exist. Some 
consist of hydrophilic polymers, which swell and form a gel network upon contact with 
gastrointestinal fluids, hereby controlling drug release. Others rely on lipases and bile salts to 
digest the hydrophobic matrix, thus gradually releasing the active ingredient [6]. Establishing a 
pharmacokinetic-pharmacodynamic (PKPD) model for different controlled-release formulations of 
oxycodone in healthy subjects is the first step towards investigating clinically relevant PKPD 
alterations in various patient groups, as this will serve as a reference to help explain variations and 
optimise treatment regimens. Pupillometry has previously been acknowledged as a reliable and 
objective surrogate for the pharmacodynamic effects of opioids, as it reflects the central opioid 
receptor activity [7–10]. A negative correlation has also been found between the extent of pupil 
constriction and analgesic effect after morphine exposure [11]. Furthermore, the onset of analgesia 
occurred simultaneously with the induced miosis [11]. We hypothesised that the 
pharmacodynamic (PD) time-course of controlled-release formulations would be explained 
entirely by the pharmacokinetic (PK) time-course, and that this would differ from the PK time-
course of the oral solution in healthy subjects. The aim of this study was to characterise and 
evaluate the PKPD relationship of oxycodone following two generically marketed but differing 
controlled-release formulations and an oral solution in healthy subjects, using pupil diameter as a 
PD endpoint.
Materials and methods
Study design 
This study was conducted in accordance with the Declaration of Helsinki, local regulations, the 
Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies [12] 
and International Conference on Harmonisation Good Clinical Practice (GCP) guidelines. The 
protocol, amendments and informed consent form were approved by The North Denmark Region 
Committee on Health Research Ethics, Denmark (N-20170039), the Danish Health and Medicines 
Authority (EudraCT No.: 2017-000732-34), the Data Protection Agency (ID. No. 2017-125), 
Denmark and registered in clinicaltrialsregister.eu (2017-000732-34). The study was monitored by A
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the GCP unit, Aalborg and Aarhus University Hospitals, Denmark. All participants gave their 
informed consent and received remuneration for their contribution. 
The study was conducted according to a randomised, semi-blinded, three-way crossover design 
with at least 1-week washout interval. Researchers and nurses were blinded until all subjects had 
completed the study. The laboratory technician determining the plasma concentrations of 
oxycodone was fully blinded. The healthy subjects were unaware of dose and functionality of the 
different formulations; however, the drug formulations did not have identical appearances, hence 
being “semi-blinded”. The study was conducted in a laboratory at Mech-Sense, Department of 
Gastroenterology and Hepatology, Aalborg University Hospital in the period of August 2017 to 
February 2018. Each subject fasted 8 h prior to study days and was supplied with standardised 
meals every 3 h post-dose until discharge. Water was allowed ad libitum except for 1 h before and 
after drug administration. Additionally, cordial or juice was allowed ad libitum at 3 h post-dose. 
Subjects were discharged after the 12 h blood sample and returned the subsequent morning for the 
24 h blood sample. The study was conducted in a quiet laboratory setting under dimmed light 
conditions and tests were performed by trained investigators. Subjects were requested to restrict 
medications (apart from contraception), supplements, alcohol and products containing grapefruit 
48 h prior to and during study days. Study data were collected and managed using REDCap 
electronic data capture tools hosted at Aalborg University Hospital [13].
Study population
An approximately even distribution of fifteen healthy, opioid-naïve men and women of Northern 
European descent, aged 25-80 years with a BMI between 18.5-29.9 kg/m2 were recruited. An 
objective examination of the subjects was performed by a medical doctor. Subjects were judged 
healthy if they had no concurrent or past medical history of any chronic diseases, had normal vital 
signs and normal or non-clinically significant eGRF, ALAT, bilirubin, haemoglobin and HbA1c 
levels. Fertile females were required to have a negative pregnancy test and use an effective 
contraception method during the entire study period. Subjects were excluded if they had: Any 
known allergies to oxycodone or similar compounds, persistent pain, participated in other 
intervention studies within 14 days prior to study inclusion, expected need for new medication or 
surgery within the time course of the study, daily alcohol and/or nicotine consumption, daily 
intake of any medication and/or herbal medicines that could influence the study results (e.g. strong A
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inhibitors or inducers of CYP enzymes and P-glycoprotein), were lactating and/or had a personal 
or family history of substance abuse. 
Study medication
On study days each subject received a single 10 mg oral solution oxycodone (Oxynorm®, oral 
liquid mixture 1mg/ml; Norpharma A/S / Mundipharma A/S, Vedbaek, Denmark) or 20 mg 
controlled-release (water-swellable matrix) oxycodone (Oxycodone hydrochlorid “Lannacher”, 
controlled-release tablet 20 mg; Lannacher Heilmittel Ges.m.b.H, Lannach, Austria) or 20 mg 
controlled-release (lipid-based matrix) oxycodone (Oxycodone Depot “Sandoz”, controlled-
release tablet 20 mg; Sandoz A/S, Copenhagen, Denmark) in a randomised order.  Subjects 
received the oral solution with 50 ml water and the tablets with 240 ml water. Each of the three 
drug formulations used was from the same batch. 
Blood sampling 
Venous blood samples were collected into K2-EDTA vacutainers for quantification of oxycodone 
plasma concentrations before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.33, 2.66, 3, 3.33, 3.66, 4, 5, 6, 8, 12 
and 24 h after drug administration. Blood samples were immediately cooled and subsequently 
centrifuged at 4C at 2500 revolutions per minute for 15 minutes. Plasma was separated into 
duplicate polypropylene tubes and then stored at -80C until analysis. The time between sample 
collection and freezer storage did not exceed 2 h.
Pupillometry
Pupillometry was used as an objective surrogate for the central nervous system (CNS) actions of 
oxycodone. Pupillary recordings were performed using a digital infrared hand-held NeuroOptics 
VIP 200 pupillometer (NeuroOptics, Irvine, CA, USA). A tight-fitting eyecup covered the eye 
during pupillary recordings. Recordings were conducted on the right eye, in a room with 
controlled dimmed lighting after each blood sampling. If subjects left the room or used an 
electronic device, a minimum of two minutes of dark adaption was mandatory before performing 
the pupillometry recording. Subjects were asked to look at the same fixation point with the left eye 
for each measurement. The pupil diameter was calculated as a mean of three successive 
recordings, which had a standard deviation below 0.1 mm. A
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Plasma analysis of oxycodone
Plasma samples were analysed for contents of oxycodone and noroxycodone on a Bruker Avance 
UHPLC (Bruker Daltonik, Bremen, Germany) equipped with a CTC-PAL-xt autosampler with 
cooled sample compartments (10 °C) and a column oven held at 40°C. The UHPLC eluate was 
directed to a Bruker Evoq Elite triple quadrupole MS equipped with a heated electrospray 
ionisation source. Separation was obtained using a Phenomenex (Phenomenex, Torrance, CA, 
USA) Kinetex XB-C18 column (50 mm × 2.1 mm i.d., 1.7 µm particle size) equipped with a guard 
column. Protein was removed from the plasma samples through protein crash by ice-cold 
acetonitrile; 600 l acetonitrile and 10 l internal standard (containing 300 ng/ml oxycodone-d3 
and 100 ng/ml noroxycodone-d3; both from Cerrilliant Corporation, Round Rock, TX, USA) were 
added to an Eppendorf tube followed by the addition 200 L plasma. The samples were vortexed 
for 10 seconds before centrifugation at 16,000 × g for 10 minutes. The supernatant was transferred 
to a deep well plate and evaporated to dryness in an RVC 2-25 CDPlus rotational vacuum 
concentrator (Christ, Osterode am Harz, Germany) set at 25°C. The residue was reconstituted in 
100 L mobile phase A. The reconstituted samples were analysed for contents of oxycodone and 
noroxycodone by injecting 15 L on the above-mentioned UHPLC-TQMS system. The analytes 
were separated using a solvent system consisting of 15 mM ammonium formate in Milli-Q water 
(pH 3.5) (mobile phase A) and 15 mM ammonium formate in 90% acetonitrile (mobile phase B). 
HPLC grade acetonitrile was purchased from VWR – Bie & Berntsen (Søborg, Denmark), water 
was prepared by deionization and 0.22 µm membrane filtration using a Milipore system (Billerica, 
MA, USA), and ammonium formate was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
The initial mobile phase composition of 3.5% B was changed to 75% B over 2 minutes after 
injecting the samples. The solvent composition was increased to 100% B at 2.1 min and kept at 
100% B until 3 min., before returning to 3.5 %B (3.1 min) for column equilibration for additional 
2.9 min. For the entire 6-minute cycle, the flow rate was kept at 500 L/min. The mass 
spectrometer was operated in positive mode with multiple reaction monitoring. The ion transitions 
were m/z 316.2/298.0 and 316.2/241.0 for oxycodone, 302.2/284.0 and 302.2/227.0 for 
noroxycodone, 319.2/301.0 and 319.2/244.0 for oxycodone-d3, and 305.2/287.0 and 305.2/230.0 
for noroxycodone-d3. 
The standard curves ranged from 0.1 to 75 ng/ml and 1–22.5 ng/ml for oxycodone and 
noroxycodone (both from Cerrilliant Corporation Round Rock, TX, USA), respectively. The A
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curves were fitted with quadratic regression. Two QC plasma samples with either 0.6 ng/mL 
oxycodone and 3 ng/ml noroxycodone or 60 ng/ml oxycodone and 21.6 ng/ml noroxycodone were 
analysed each day of analysis, and relative standard deviation was ≤ 15% for oxycodone and ≤ 
17% for noroxycodone.
Safety monitoring 
Safety and tolerability evaluations included an assessment of adverse events. If necessary, 
monitoring of vital signs, oxygen saturation and physical examinations were performed. Subjects 
were asked before and 1.5, 3, 6, 12 and 24 h after drug administration to rate the degree of 10 
well-known and/or common side-effects of oxycodone. The rating scale was as follows: (0) none, 
(1) slight, (2) moderate, (3) high degree and (4) very high degree. The sum of side-effects scores 
were compared between formulations by repeated measures ANOVA. P < 0.05 was considered 
significant and the statistical analysis was performed using R software [14] (Version 3.3.3).
General modelling procedure 
Models were fitted to population data using non-linear mixed effect modelling (NONMEM) 
(version 7.4; ICON Development Solutions, Ellicott City, MD, USA) with the Wings for 
NONMEM interface (http://wfn.sourceforge.net) and IFort compiler. The first order conditional 
estimation with interaction (FOCE-I) analysis was used within NONMEM. Unless stated 
otherwise, the inter-individual variability of parameters was assigned a log-normal distribution 
across the population. A combined additive and proportional residual error model was used, but 
was reduced to either proportional or additive if an error term was very small and did not improve 
the model fit. Selection criteria for the base model were based on mechanistic plausibility, a 
statistically significant (P < 0.05) improvement of the fit (3.8-unit decrease in the objective 
function for the addition of a single parameter) and visual inspection of standard goodness-of-fit 
diagnostic plots. The final model was also required to pass the covariance step. Visual predictive 
checks (VPC) based on 1000 simulations of the index dataset were used to evaluate the predictive 
performance of the adequacy of the final model in describing the observed data.  
A sequential PKPD modelling approach was used, whereby the PK component of the model was 
developed first, with the PD model developed sequentially using the PPP&D (Population PK 
Parameters and Data) method with the PK model parameters fixed at the previously determined 
values and the PK data retained during the PD model estimation step [15]. A
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Models accounting for below limit of quantitation (BLOQ)-censored data were investigated using 
the YLO and M3 methods [16]. The YLO and M3 methods provide complimentary methods for 
attempting to utilize BLOQ data. With the YLO method likelihood assumes all values are 
censored at the lower limit of quantification. In contrast, the M3 method estimates the likelihood 
at times measurements BLOQ. We chose the M3 method (which does not assume that 
measurements are > 0) over the M4 method (which assumes measurement must be > 0).  Although 
this may be controversial in the literature, we chose the M3 method as we believe that it is indeed 
theoretically possible that a measure concentration may be <0. Processing NONMEM output and 
generating plots were conducted with the R software [14] (Version 3.3.3 or later) using gglot2, 
plyr, doBy and scales packages and their associated dependencies. 
Pharmacokinetic modelling
A PK model for oxycodone was developed and fitted simultaneously to the data from three 
formulations of oxycodone, thus allowing for differences in relative bioavailability (oral solution 
reference value 100%), absorption rate constants and absorption lag to be examined. Standard 1-, 
2- and 3-compartment models with first-order absorption were fitted to the plasma oxycodone 
concentration-time data. Correlations between parameters were examined. The Omega BLOCK 
functionality of NONMEM was investigated on models that had highly correlated (>0.5) ETAs. 
All base models were investigated with allometric scaling with total body weight referenced to 70 
kg and fixed exponents of 0.75 for clearance and 1 for volumes. Population parameters were tested 
for between-occasion variability as a random effect. Potential significant covariates were 
identified by visualising plots of covariates versus between-subject variability (BSV) of parameter 
estimates. Physiologically plausible covariates (e.g. vomit, sex, age) were evaluated for statistical 
significance using a stepwise covariate modelling of forward addition and backward elimination 
[17]. The statistical criteria for retaining a covariate in the model was P < 0.01 during forward 
addition and P < 0.001 for backward elimination. 
Pharmacodynamic modelling
Direct effect, effect-compartment (linked effect) and turn-over models with linear, sigmoidal Emax 
and simple Emax concentration-relationships were tested as described in more detail by Upton et 
al., 2014 [18]. All models were tested with the oxycodone drug effect as either additive or 
proportional to the baseline value of the PD metric (pupil diameter). The distributions of the A
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baseline PD parameters were assumed to have a normal distribution. Potential covariates were 
screened and evaluated as described for the PK model development.
Simulations 
Simulations, using the final PKPD model, were used to investigate the magnitude of a slower 
absorption rate constant for the controlled-release formulation (kaCR) on specific pharmacokinetic 
and pharmacodynamics endpoints, thus predicting what might happen to the time-course of 
analgesia. The kaCR could potentially be lower for patients with gastrointestinal dysfunctions such 
as Crohn’s disease, due to a thickened bowel wall and mucosal lesions. Fat maldigestion, which 
also applies for patients with chronic pancreatitis, may also influence drug release for the lipid-
based controlled-release formulation [19,20].  
Simulations for 2000 subjects receiving 10 mg controlled-release oxycodone every 12 hours for 4 
days were performed. Simulations were based on an individual weight set to 70 kg and performed 
for each sex. Two absorption rate constants were tested (125% and 150% of the final model 
absorption half-life). These values were chosen based on a previous modelling work on 
controlled-release oxycodone [21]. Non-compartmental exposure metrics of oxycodone 
concentrations (AUCt, Cmax and Tmax) and time to maximum PD effect (TPDMAX) and maximum 
PD effect (PDmax) were calculated based on the last dosing interval. Simulations were conducted 
using the mrgsolve package in the R software [14] (Version 3.3.3 or later). 
Shiny application 
The final model was incorporated within a Web application which allows users to rapidly simulate 
clinical scenarios. The application is built using the Shiny package for R, and simulations are 
performed using the mrgsolve package [22].
Statistical analysis 
Previous bioequivalence studies have used 12-30 subjects. The present study used 3 cross-over 
arms, thus further increasing the power of the study. Thus, 15 subjects were considered an 
appropriate sample size. Demographic variables were compared using Student’s t-test or Kruskal-
Wallis Rank Sum Test, depending on data distribution, which was assessed using Shapiro Wilk 
testing and visual inspection of density plots and Q-Q plots. Statistical significance was assumed 
at P < 0.05. All data were analysed using the R software [14] (Version 3.3.3 or later). A
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Results
Study population and pharmacokinetic/pharmacodynamic data 
Fifteen (8 males, 7 females) healthy opioid-naïve volunteers (mean age 32.2  7.64, range 25-46 ±
years) participated and completed all three treatment visits. Relevant demographics are 
summarised in Table 1. Benzoyl peroxide (N = 1) against acne and contraceptive methods (N = 6) 
were the only medications used amongst subjects. Significant sex differences were seen for height 
(P = 0.001) and weight (P = 0.003); however, there was no significant sex difference in body mass 
index (P = 0.247). 
---------------------------------------------------Table 1 near here ---------------------------------------------
In total, 850 blood samples were obtained and 853 pupil diameter measurements were performed. 
Overall, 7.4 % of the oxycodone plasma concentration data were unavailable. This was mainly due 
to plasma concentrations being below the lower level of quantification, predominately at the 
beginning or end of sampling periods. Additionally, 0.23 % of the pupil measurements were 
missing. This was due to one subject experiencing side-effects at the time of measurement and 
another subject not returning for the 24 h sampling. Measured data are presented in Figure 1. 
Models accounting for below the limit of quantitation (BLOQ)-censored data were investigated 
using the YLO and M3 methods [16]; however, these were characterised by unreliable 
minimisation and covariance step status. Samples below the limit of quantitation were thus 
excluded a priori from the data set (M1 method). 
------------------------------------------------------Figure 1 near here ------------------------------------------
Pharmacokinetic model 
The PK of the three oxycodone formulations was best described by a 2-compartment distribution 
model compared to 1-compartment or 3-compartment models (Table S1, supplementary 
information). The model was allometrically scaled for total body weight referenced to 70 kg. The 
model retained both a proportional and an additive residual error term. Structural covariates 
included a formulation effect on the first-order absorption rate which was 80.1% slower for the 
controlled-release tablets (ka = 0.94 h-1 vs. 0.19 h-1 for the oral solution and controlled-release A
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formulations, respectively). Additionally, an absorption lag (ALAG) of 0.23 h was seen for the 
controlled-release tablets. The occurrence of vomiting, age and sex were tested as possible 
covariates, but no important relationships were found. A significant drop in the objective function 
was seen upon fitting separate absorption rate constants and bioavailability for the oral solution 
and controlled-release formulations. The estimated relative bioavailability and absorption rate 
constant were 0.33% and 1.1% different for the two controlled-release formulations compared to 
the oral solution, respectively. However, these models were largely over-parameterised 
(condition number > 100) and/or did not pass the covariance step. Additionally, fitting a common 
bioavailability parameter for the two controlled-release did not improve the objective function. 
Therefore, both controlled-release formulations shared common parameters for the absorption 
rate-constant and the relative bioavailability was set to 1 for all formulations. Similarly, including 
between subject variability on bioavailability and absorption rate constant improved the model 
significantly, but this was discarded due to over-parameterisation of the model and an adverse 
impact on parameter precision. The final model population parameters are summarised in Table 2 
and show good parameter precision (%SE < 30% for all parameters). The terminal half-life of 
oxycodone was estimated to be 3.2 h. Figure 2 presents the adequacy of the final model in key 
diagnostic plots following the three oxycodone formulations, with no major systematic bias in the 
structural and residual error models. The VPC plot of the final PK model showed good predictive 
performance for the observed oxycodone concentrations as represented by the good overlay of the 
median and 5th percentiles and 95th percentiles of the observed and the corresponding prediction 
intervals and 90% confidence intervals of the simulated concentrations (Figure 3). The model 
tends to slightly underpredict the observed 5th percentile of oxycodone concentrations; however, 
the observed median, 5th and 95th percentiles remain within the corresponding 90% confidence 
intervals of simulated concentrations (Figure 3). Similar VPC plots were obtained when 
oxycodone data were stratified on formulation (Figure S1, supplementary information).
-------------------------------------------------Table 2 near here ------------------------------------------------
--
------------------------------------------------Figure 2 near here ------------------------------------------------
--
------------------------------------------------Figure 3 near here ------------------------------------------------
-- A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Pharmacodynamic model 
Pupil diameter alteration was used as a PD endpoint for the CNS actions of oxycodone. Results 
from the modelling procedure indicated a proportional, Emax model linked to an effect-delay 
compartment to best explain the PD of oxycodone effect-delay. The delay between changes in 
plasma oxycodone concentration and effect was best described by an effect delay term (ke0). In the 
final model, ke0 was estimated to be 2.92 h-1, giving an effect delay half-life of about 14 min, with 
high inter-individual variability (BSV-SD = 0.516). A sex covariate was found on EC50 
(concentration at which the effect is 50 % of Emax (maximum effect)), where the EC50 was 41.1 % 
lower for males (31.1 g/L) compared to females (52.8 g/L) indicating a higher potency of the 
total (bound + unbound) drug in males. The population estimates of the final PD model are 
summarised in Table 3 and show acceptable precision. Figure 4 shows the key diagnostic plots for 
the final PD model following the three oxycodone formulations. The individually predicted pupil 
diameters were comparable with the observed measurements with no indications of major bias. 
Model simulations were sufficient to describe the PD data for the different oxycodone 
formulations, as indicated by the VPC plots (Figure 5). 
------------------------------------------------Table 3 near here -------------------------------------------------
-
------------------------------------------------Figure 4 near here ------------------------------------------------
--
------------------------------------------------Figure 5 near here ------------------------------------------------
--
Simulation
The population effects of a slower absorption rate constant are shown in Table 4. A 25% (kaCR = 
0.15) and 50% (kaCR = 0.13) increase in absorption half-life resulted with an approximate 5% and 
7% reduction of Cmax for both sexes, respectively. These changes in absorption resulted in a 
maximum PD effect (PDmax) slightly decreased (as the pupil diameter 1 mm larger) for females. 
Time to PDmax was prolonged by 30 minutes for males.
A
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------------------------------------------------Table 4 near here -------------------------------------------------
-
Shiny application 
A “shiny” application for the final model can be assessed at (https://acp-
unisa.shinyapps.io/oxycodonepkpd/). The application has been designed to allow users to assess 
the influence of covariates (formulation, sex and weight), varying dose-regimen and changes to 
the absorption rate constant on 1) the concentration-time profiles and exposure metrics of 
oxycodone, and 2) changes in pupil diameter, which is a surrogate for what might happen to the 
time-course of analgesia. Users may change parameter values and add prediction intervals by 
selection and/or changing the sliders. Users are required to click the “Simulation” button to update 
the plot after selecting the desired parameters’ setting. Simulated exposure/response metrics data 
can be downloaded as a *.csv file by pressing the “download” button. 
Safety assessments 
No subject experienced any unknown, severe, harmful or persistent adverse event with regard to 
oxycodone. The most common side effects reported were sedation, dry mouth, dizziness and 
nausea. Four out of the fifteen subjects vomited at least once. A total of three subjects vomited 
after receiving the oral solution, two after the water-swellable controlled-release formulation and 
one after the lipid-based controlled-release formulation. All vomiting incidents occurred >2 h 
post-dose for the oral solution and >12 h post-dose for the controlled-release tablets. No difference 
in the overall degree of side-effects was reported for the three formulations (P > 0.05) (Figure 6). 
------------------------------------------------Figure 6 near here ------------------------------------------------
--
Discussion
A population PKPD model was developed to describe the exposure-response relationship of oral 
solution and two monophasic controlled-release oxycodone formulations using data from 15 
healthy subjects. The generically marketed controlled-release formulations had the same PD 
profile despite different formulation technologies, and there were no differences in the PK of these 
formulations. The controlled-release formulations differed from the oral solution by a delayed and A
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slower absorption, which explains the prolonged onset and offset of action. These findings are 
consistent with the marketed PK and PD properties of the applied study formulations. The model 
also indicated that oxycodone was more potent in males compared to females. Moreover, 
simulations revealed that the exposure-response relationship of controlled-release oxycodone was 
minimally affected for lower absorption rate constants.
Oxycodone pharmacokinetics
The PK of oral solution oxycodone in healthy subjects has previously been described by a one-
compartment model with an absorption lag [23–26]. Results from work by Lalovic et al. also 
mainly supports a one-compartment model; however, they noted that some concentration-time 
profiles were better described by a two-compartment model [27]. Kokki et al. modelled the PK of 
several oxycodone formulations simultaneously (including intravenous, oral immediate-release 
and a biphasic oral controlled-release oxycodone) [28]. This model was based on data from elderly 
patients undergoing cystoscopy and showed that oxycodone pharmacokinetics was best described 
by a two-compartment model similar to that reported in the current paper. These findings highlight 
the limitation of an individual fitting iterative two-stage approach in comparison to the non-linear 
mixed-effects population approach used in the present work and by Kokki et al. (15). Additionally, 
parameter estimates were similar to those obtained by Kokki et al., but differed from the rest of the 
studies mentioned. Moreover, the terminal elimination half-life (T½elim)  of 3.2 h was within the 
range (T½elim =  2.3-6.7 h) of previously determined half-lives [26,28–33]. The controlled-release 
formulations showed a more gradual drug absorption compared to the oral solution. This was 
indicated by a lower absorption rate constant. Additionally, the bioavailability was best modelled 
as a fixed parameter set to 1, which implies that the relative bioavailability is 100%. Both findings 
are in agreement with results of Mandema et al. [26] and Kokki et al. [28]. In contrast to all above-
mentioned studies, no lag time could be detected for the oral solution in this study. Possible 
reasons for these minor variations could be related to the limited number of subjects and large 
inter-individual variability in the PK profiles (Figure 1). This suggestion is partly supported by the 
observed over-parameterisation, when modelling separate lag times for the three formulations. 
CNS effects
Lalovic and co-workers have described the concentration-analgesic relationship using 
pupillometry of oral immediate-release oxycodone by the classical Emax model with an effect delay A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
half-life (t½keo) of 11 min [27]. This characterisation is in good accordance with our findings, 
although our model showed a slightly longer t½keo of 14 min. Other studies have described oral 
solution oxycodone by a linear effect relationship using subjective experimental pain measures 
and found no effect delay [24,25]. Staahl et al. found similar results, with effect delay ranging 
from 12-22 min for thermal and electrical skin stimulation [23]. 
Contradictory results regarding a correlation between opioid potency and gender exist [34–39]. In 
most animal studies, morphine and oxycodone had a higher potency in males compared to females 
[36,38]. Kim et al. found higher pain relief in men compared to females after equivalent 
oxycodone dosages [39]. In contrast, human males have been found to require 30-40% more 
morphine to obtain similar analgesic effects compared to females [34]. Similarly, a recent patient 
study also found that men required 28% more oxycodone than females to blunt the intubation 
reaction [37]. Our model found that oxycodone is more potent in males compared to females. Our 
finding suggests that the dose-effect difference between males and females is not due to 
pharmacokinetics, as no gender differences was found in the PK model. Nevertheless, it can be 
explained by an unknown sex-related pharmacodynamic mechanism for which we did not have a 
covariate to explain.  
The PD effect of oxycodone was well described across formulations demonstrating different 
absorption profiles. We did not attempt to develop PK models for oxycodone metabolites. The 
main metabolite, noroxycodone, does not appear to exert central analgesic effects [27,40]. 
Oxymorphone, which is the second most abundant metabolite exhibits 8 times the potency and 40 
times the affinity on -opioid receptor as compared to oxycodone. Despite this, the majority of 
studies suggest that the contribution of oxymorphone to the pharmacodynamic effects of 
oxycodone administrations is minimal, presumably attributed to the very low plasma 
concentrations, rapid glucuronidation to an inactive metabolite and/or the low rate of crossing the 
blood-brain-barrier [24,27,41–44]. Nevertheless, opposing results have been demonstrated by 
Samer et al., although the impact on pupil size was not as substantial as other pharmacodynamic 
parameters, thus questioning the central effects of oxymorphone [45]. Incorporating metabolites in 
future models could clarify this. 
Simulations
The presented simulation results (Table 4) showed minimal alterations of PK and PD metrics for 
lower absorption rate constants. It is, however, important to emphasise that the performed A
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simulations lack essential physiological parameters. Thus, in reality, things may be very different 
and dosage adjustments may still be necessary for some patients to obtain satisfactory pain relief 
and prevent adverse events depending on the formulation design. More studies are needed to 
evaluate the clinical significance of these simulated results.
Degree of side-effects
In a study by Christrup et al., sedation tended to be more pronounced after an immediate-release 
formulation of morphine as compared to a controlled-release formulation [5]. Our results found no 
association between a higher degree of side-effects and formulation type. This result may be 
biased by the different dosages, where the oral solution was half that of the controlled-release 
formulations. Hence, fewer side-effects are likely reported for the oral solution.  
Strengths and limitations 
The randomisation and cross-over design, frequent, objective measurements and limited missing 
data strengthen the characterisation of the PKPD model by minimising bias, periodic effects and 
variance in PK and PD measurements. However, the design of this study also has some 
limitations. Subjective pain measurements would have supplemented the PD model, although 
these measurements often have drawbacks (e.g. limitation of frequent sampling, placebo-effect). 
Results from several studies have shown that pupillometry as used here is a valid biomarker for 
the central effects of opioids [8,11,46]. Additionally, a placebo treatment arm would have allowed 
for controlling for circadian modifications of the pupil diameter, which has been shown previously 
[47]. However, a placebo arm was not included due to practical and logistical issues. The duration 
of the study was 7 months, and including a placebo-arm would have expanded the study period 
significantly and participants would have had more days in the study. Additionally, the main aim 
of the study was to investigate pharmacokinetic differences between oral solution and two 
different controlled-release formulations. Thus, it was decided that the value of a placebo-arm was 
limited compared to the extra resources. 
Subjects were discharged after 12 hours, as this was more convenient and less time-consuming for 
the subjects and study personnel. Nevertheless, we do not believe that this would introduce 
considerable variability to our data, because the measures are objective and oxycodone has a half-
life of approximately 3 hours.     A
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In contrast to the study by Kokki et al., the absolute bioavailability of the different formulations 
could not be estimated, as intravenous oxycodone data were not included in the design [28]. This 
was mainly due to the comprehensiveness of the study protocol. Additionally, more complex 
absorption models (slow and fast absorption) were not tested because the controlled-release 
formulations used in the current study were monophasic unlike the one used by Kokki et al. [28], 
which had a biphasic drug release. 
While it might have been interesting to examine genetic polymorphisms of especially the -opioid 
receptor (OPRM1) and the metabolising enzymes CYP3A4/5 and CYP2D6, as potential 
covariates, the purpose of this work was focused on formulation effects on the PKPD profile of 
oxycodone. We can conclude that intestinal region-selective CYP450 expression does not impact 
the absorption processes of the different oxycodone formulations, as no differences in 
bioavailability was found between the oral solution and controlled-release formulations, despite 
clear differences in the time-course of absorption.
The establishment of the presented model is based on relatively young, healthy adults (age range 
25-46 years), even though the included age range was deliberately broad to enhance the likelihood 
of matching future studies. Consequently, limiting predictions for other age groups, patients and 
different types of pain. However, the model can help outline possible differences in PKPD 
profiles, when comparing results obtained in patient groups with gastrointestinal dysfunction, 
when using the same medications and study design. Additionally, only monophasic preparations 
of two distinct controlled-release delivery systems were used. Results may therefore not be 
transferable to biphasic controlled-release formulations and other types of delivery systems.
In conclusion, a population PKPD model was developed for different oral oxycodone formulations 
based on data from healthy subjects. Expectedly, the diverse delivery systems of two monophasic 
controlled-release formulations had the same exposure-response relationship. Thus, indicating 
interchangeability in humans with normal gastrointestinal function. The controlled-release 
oxycodone formulations showed a smoother absorption profile and a prolonged onset and offset of 
action compared to oral solution oxycodone, thus being more suitable for persistent pain and 
chronic opioid users. The PD differences for the formulations were entirely explainable by 
pharmacokinetics differences secondary to different absorption profiles. Finally, the need for 
dosage adjustments to secure optimal oxycodone therapy for patients with gastrointestinal A
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dysfunction (e.g. Crohn’s disease, chronic pancreatitis etc.) using different formulation designs, 
should still be investigated.
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Tables 
Table 1. Study population characteristics.
 Female Male P-value
No. of subjects 7 8 -
Age (yrs.) 35.00 (9.24) 29.75 (5.39) 0.195
Height (cm) 170.86 (6.47) 186.38 (7.35) 0.001
Weight (kg) 68.63 (8.84) 86.39 (10.18) 0.003
BMI (kg/m2) 22.30 [21.70 - 25.61] 24.03 [23.13- 26.03] 0.247
Data are expressed as mean (standard deviation) or median [interquartile range]. Group comparisons were performed 
using Student’s t-test or the Kruskal-Wallis Rank Sum Test, depending on data distribution. BMI = body mass index. 
Table 2. Pharmacokinetic parameter estimates for the best pharmacokinetic model.
Parameter Symbol Unit Pop valuea %RSE BSV(SD) %RSE ETA P value Shrinkage (%)
CL/F 1 L/h 79.4 9.0 0.318 11.8 0.992 0
V1/F 2 L 80.1 29.3 1.005 17.3 0.985 0.7
Q/F 3 L/h 83.3 24.0 - - - -
V2/F 4 L 164 7.0 - - - -
kaSOL 5 h-1 0.94 26.0 0.342 16.8 0.984 5.9A
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error; BSV = between subject variability; SD = standard deviation; %CV = percent coefficient of variation. Symbols 
relate to the control stream (Please see the supplementary information);  = THETA,   = SIGMA.
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kaCR 6 ratio -0.801 4.4 - - - -
ALAG 7 h 0.23 2.9 - - - -
Residual error
   Proportional error
   (ERRCV)
1 %CV 37.4 7.1 - - - -
   Additive error
   (ERRADD)
2 g/L 0.5 19.3 - - - -
CL = total body clearance; F = bioavailability; V1 (or V2) = volume of first (or second) compartment; Q = inter-
compartmental clearance; kaSOL = absorption rate constant for the oral solution; kaCR = effect on absorption rate 
constant for the controlled-release formulations; ALAG = lag time for the controlled-release formulations %RSE = 
percent of relative standard error; BSV = between subject variability; SD = standard deviation; %CV = percent 
coefficient of variation. Symbols relate to the control stream (Please see the supplementary information);  = THETA,  
 = SIGMA. 
aPopulation typical value. Bioavailability was best modelled as a fixed parameter = 100 %.  
Table 3. Pharmacodynamic parameter estimates for the best pharmacodynamic model.
Parameter Symbol Unit Pop 
valuea
%RSE BSV(SD) %RSE ETA P value Shrinkage 
(%)
EBASE 8 mm 5.4 2.4 0.169 13.7 0.955 0
EC50 9 g/L 52.8 15 0.227 15.5 0.823 8.1
ke0 10 h-1 2.92 3.1 0.516 72.2 0.843 17.1
SEXCOV 11 ratio -0.411 32.8 - - - -
Objective function 2671.56
Residual error
   Proportional error
   (ERRCVPD)
3 %CV 9.2 5.6 - - - -
EBASE = baseline effect; EC50 = concentration at which the effect is 50 % of Emax (maximum effect); ke0 = effect 
compartment elimination rate constant; SEXCOV = effect of male sex on EC50; %RSE = percent of relative standard A
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relate to the control stream (Please see the supplementary information);  = THETA,   = SIGMA.
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Table 4. Simulation results and predicted effects on pharmacokinetic and pharmacodynamic endpoints for 10 mg controlled-release oxycodone, stratified by sex. 
Formulation Metric Female Male 
PKPD model
(kaCR = 0.19)
kaCR = 0.15 kaCR = 0.13 PKPD model
(kaCR = 0.19)
kaCR = 0.15 kaCR = 0.13
AUCt (ng·h/ml) 126.5 126.5 126.5 126.5 126.5 126.5
Cmax (ng/ml) 21.9 20.8 20.4 21.9 20.8 20.4
Tmax (h) 2.5 2.5 2.5 2.5 2.5 2.5
PDmax (mm) 3.6 3.7 3.7 3.2 3.2 3.2
10 mg controlled-release 
oxycodone
TPDmax (h) 3.5 3.5 3.5 3.0 3.5 3.5
kaCR = absorption rate constant for the controlled-release tablets; AUCt = area under the concentration curve, Cmax = maximum concentration; Tmax = time to maximum 
concentration; PDmax = minimum pupil size (maximum effect); TPDmax = time to maximum effect (PDmax). All metrics are based on the last dosing interval. 
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Figure legends 
Figure. 1. Observed oxycodone plasma concentrations and pupil diameter data by formulation. 
Oxycodone plasma concentration is shown in red. Pupil diameter is shown in blue. Symbols are measured data. Solid 
line is the median of the measured data. Data are log-transformed. CRF = controlled-release formulation. 
Figure 2. Diagnostic plots for oxycodone concentrations following oral solution oxycodone (red), controlled-
release water-swellable oxycodone tablets (blue) and controlled-release lipid-based oxycodone tablets (green). 
Symbols are data points, the solid black line is a line of identity with slope 1 or 0, and the red lines are a loess-smooth 
of the data. CWRES = conditional weighted residuals, conc = concentration, CRF = controlled-release formulation.
Figure 3. Visual predictive check of oxycodone using the final pharmacokinetic model. 
Symbols represent observed oxycodone concentrations. The shaded areas represent the 90% confidence interval of the 
5th, 50th, 95th percentiles of the simulated concentrations. The solid red line represents the median of the observed 
concentrations. The dashed red lines represent the 5th and 95th percentiles of the observed concentrations. The 
horizontal dotted lines represent the lower limit of quantitation of oxycodone. The black lines represent the predicted 
median with the 5th and 95th percentiles. 
Figure 4. Diagnostic plots for pupil diameter following oral solution oxycodone (red), controlled-release water-
swellable oxycodone tablets (blue) and controlled-release lipid-based oxycodone tablets (green). 
Symbols are data points, the solid black line is a line of identity with slope 1 or 0, and the red lines are a loess-smooth 
of the data. CWRES = conditional weighted residuals, CRF = controlled-release formulation.
Figure 5. Visual predictive checks of the different oxycodone formulations using the pharmacodynamic model. 
Symbols represent observed pupil diameter. The shaded areas represent the 90% confidence interval of the 5th, 50th, 
95th percentiles of the simulated concentrations. The solid red line represents the median of the observed 
concentrations. The dashed red lines represent the 5th and 95th percentiles of the observed concentrations. The black 
lines represent the predicted median with the 5th and 95th percentiles. CRF = controlled-release formulation.
Figure 6. Total rating of side effects over time for each oxycodone formulation. No overall difference in total side 
effect scores was found between any of the formulations (P > 0.05). Vertical lines represent the standard error of the 
mean. Dots represent individual side effect scores. CRF = controlled release formulation, h = hours.  
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